Reflections on medical oncology: 25 years of clinical trials - Where have we come and where are we going?

Journal of Clinical Oncology

Volumn 26, Issue 1, 2008, Pages 6-8

  Booth, Christopher M ^a   Tannock, Ian ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; HEALTH CARE SYSTEM; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NOTE; ONCOLOGY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 37849023528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.8156     Document Type: Note

References (19)

1. Tannock I, Murphy K: Reflections on medical oncology: An appeal for better clinical trials and improved reporting of their results. J Clin Oncol 1:66-70, 1983
2. Hillner BE: Trends in clinical trials reports in common cancers between 1989 and 2000. J Clin Oncol 21:1850-1858, 2003
3. Tannock I, Gulanhusein A, Berthold DR: The transition from phase II to phase III studies. J Clin Oncol 25:325s, 2007 (suppl; abstr 6514)
4. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-639, 1996
5. Krzyzanowska MK, Pintilie M, Brezden-Masley C, et al: Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: Guidelines for improved reporting. J Clin Oncol 22:1993-1999, 2004
6. Booth CM, Cescon DW, Wang L, et al: Evolution of the randomized controlled trial (RCT) in oncology over three decades. J Clin Oncol 25:325s, 2007 (suppl; abstr 6516)
7. Lai R, Chu R, Fraumeni M, et al: Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol 24:1136-1144, 2006
8. Bedard PL, Krzyzanowska MK, Pintilie M, et al: Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol 25:3482-3487, 2007
9. Vale C, Stewart L, Tierney J: Trends in UK cancer trials: Results from the UK Coordinating Committee for Cancer Research National Register of Cancer Trials. Br J Cancer 92:811-814, 2005
10. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
11. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
12. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
13. Joly F, Vardy J, Pintillie M, et al: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol [epub ahead of print on August 13, 2007]
14. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
15. Ng RC, Pond GR, Tang PA, et al: Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966-2006. J Clin Oncol 25:23s, 2007 (suppl; abstr 581)
16. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
17. Krzyzanowska MK, Pintilie M, Tannock IF: Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 290:495-501, 2003
18. Djulbegovic B, Lacevic M, Cantor A, et al: The uncertainty principle and industry-sponsored research. Lancet 356:635-638, 2000
19. Peppercorn J, Blood E, Winer E, et al: Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109:1269-1246, 2007